The FDA defines biosimilar interchangeability as requiring a higher standard than mere similarity: an interchangeable biosimilar must produce the same clinical result as the reference product in any given patient, and for products administered more than once, the risk of switching must be no greater than continuing on the reference product
Why Traditional Metrics Undermine Engagement Most programs still rely on weight and BMI as primary indicators of progress
A promising future for GLP-1 therapies Accumulating evidence suggests that GLP-1 agonists represent a new therapeutic avenue in the management of skin diseases, particularly for patients with psoriasis , hidradenitis suppurativa , Hailey-Hailey disease and acanthosis nigricans
Vogue - How to Build Vitamin C Into Your Skin-Care Regimen 3
Ozempic (semaglutide) is part of a new generation of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which was originally approved for the treatment of type 2 diabetes
Semaglutide improves insulin resistance through direct metabolic effects and indirect effects from weight loss
